Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis

BACKGROUND: Trifluridine/tipiracil plus bevacizumab (FTD/TPI + BEV) has shown efficacy and tolerability in refractory metastatic colorectal cancer (mCRC). Because randomized controlled trial (RCT) data comparing FTD/TPI + BEV with FTD/TPI are lacking, this meta-analysis evaluated outcomes with both...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshino, Takayuki, Taieb, Julien, Kuboki, Yasutoshi, Pfeiffer, Per, Kumar, Amit, Hochster, Howard S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893398/
https://www.ncbi.nlm.nih.gov/pubmed/36743525
http://dx.doi.org/10.1177/17588359221146137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893398/
https://www.ncbi.nlm.nih.gov/pubmed/36743525
http://dx.doi.org/10.1177/17588359221146137

Ejemplares similares